Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension
To the Editor The Launch-HTN trial1 presented promising findings on lorundrostat for patients with resistant hypertension; however, several important considerations remain before its role in clinical practice can be fully defined.
Authors
- Tieh‐Cheng Fu (ORCID: https://orcid.org/0000-0002-8702-0391)
- Ching‐Mao Chang (ORCID: https://orcid.org/0000-0002-3853-2067)
- Ya‐Hsiang Tai (ORCID: https://orcid.org/0000-0002-0048-0652)
Institutions
- Taipei Veterans General Hospital (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- Taipei City Hospital (TW)
Publication Details
- Journal
- JAMA
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1001/jama.2025.16167
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00